BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34970563)

  • 1. The Efficacy and Prognostic Factors of the Combination of TACE and Apatinib for the Treatment of BCLC Stage C Hepatocellular Carcinoma.
    Liu S; Liu KC; Lv WF; Lu D; Zhu XH; Jiang B; Tan YL; Wang GX
    Front Med (Lausanne); 2021; 8():774345. PubMed ID: 34970563
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma.
    Chen S; Yu W; Zhang K; Liu W
    BMC Cancer; 2018 Nov; 18(1):1131. PubMed ID: 30453925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Sun T; Chen L; Kan X; Ren Y; Cao Y; Zhang W; Lu H; Zheng C
    J Oncol; 2022; 2022():1255133. PubMed ID: 35356254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-eluting bead transarterial chemoembolization followed by apatinib is effective and safe in treating hepatocellular carcinoma patients with BCLC stage C.
    Ju S; Wang W; Chen P; Li F; Li H; Wang M; Han X; Ren J; Duan X
    Clin Res Hepatol Gastroenterol; 2022 Mar; 46(3):101859. PubMed ID: 34999249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.
    Shuanggang C; Shen L; Qiu Z; Qi H; Cao F; Xie L; Fan W
    J Cancer Res Ther; 2020; 16(2):250-257. PubMed ID: 32474509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study.
    Xia WL; Zhao XH; Guo Y; Cao GS; Wu G; Fan WJ; Yao QJ; Xu SJ; Guo CY; Hu HT; Li HL
    Front Oncol; 2022; 12():961394. PubMed ID: 36249011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the Efficacy Among Transcatheter Arterial Chemoembolization (TACE)-Radiofrequency Ablation Plus Apatinib, TACE Plus Apatinib, and TACE Alone for Hepatocellular Carcinoma: A Retrospective Study.
    Ouyang T; Cao Y; Chen L; Zheng C
    Cardiovasc Intervent Radiol; 2022 Jun; 45(6):780-790. PubMed ID: 35410405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
    Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
    Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Kan X; Liang B; Zhou G; Xiong B; Pan F; Ren Y; Cao Y; Wang J; Yang F; Zheng C
    Front Oncol; 2020; 10():970. PubMed ID: 32733791
    [No Abstract]   [Full Text] [Related]  

  • 10. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
    Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
    Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Prognostic Factors of Regorafenib in the Treatment of BCLC Stage C Hepatocellular Carcinoma After Failure of the First-Line Therapy.
    Xu B; Lu D; Liu K; Lv W; Xiao J; Zhang X; Zhang Z; Chai J; Wang L
    Drug Des Devel Ther; 2023; 17():507-518. PubMed ID: 36814894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma.
    Zhang W; Chen L; Cao Y; Sun B; Ren Y; Sun T; Zheng C
    Cancer Manag Res; 2021; 13():5391-5402. PubMed ID: 34262347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
    Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy Of Apatinib In Transcatheter Arterial Chemoembolization (TACE) Refractory Intermediate And Advanced-Stage Hepatocellular carcinoma:A Propensity Score Matching Analysis.
    Qiu Z; Shen L; Chen S; Qi H; Cao F; Xie L; Fan W
    Cancer Manag Res; 2019; 11():9321-9330. PubMed ID: 31802950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of apatinib combined with transarterial chemoembolization (TACE) in treating patients with recurrent hepatocellular carcinoma.
    Gu H; Li J; You N; Wu K; Wang Z; Wang L; Zhu Y; Liu Q; Peng X; Zheng L
    Ann Transl Med; 2020 Dec; 8(24):1677. PubMed ID: 33490189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization (TACE) combined with apatinib versus TACE combined with sorafenib in advanced hepatocellular carcinoma patients: a multicenter retrospective study.
    Qiu Z; Shen L; Jiang Y; Qiu J; Xu Z; Shi M; Yu Z; Ma Y; He W; Zheng Y; Li B; Wang G; Yuan Y
    Ann Transl Med; 2021 Feb; 9(4):283. PubMed ID: 33708910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study.
    Cao Y; Sun T; Guo X; Ouyang T; Kan X; Chen L; Liang B; Wang M; Zheng C
    Front Oncol; 2021; 11():673378. PubMed ID: 34414104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study.
    Patidar Y; Chandel K; Condati NK; Srinivasan SV; Mukund A; Sarin SK
    J Clin Exp Hepatol; 2022; 12(3):745-754. PubMed ID: 35677519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.